Larvol Delta - Confo-Therapeutics-Doses-First-Subjects-in-Phase-1-Clinical-Trial-of-CFTX1554-for-the-Treatment-of-Neuropathic-Pain

CFTX-1554 - Confo Therap

https://www.businesswire.com/news/home/20220310005434/en/Confo-Therapeutics-Doses-First-Subjects-in-Phase-1-Clinical-Trial-of-CFTX-1554-for-the-Treatment-of-Neuropathic-Pain

Mar 10, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next